| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.02 [0.87, 1.20] | | < 1 | | 19% | 3 studies (3/-) | 38.9 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.58 [1.39, 1.79] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.37 [0.23, 0.60] | | > 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| irORR | 0.24 [0.03, 2.19] | | > 1 | | 0% | 1 study (1/-) | 10.3 % | NA | not evaluable | | non important | - |
| irPFS | 1.44 [1.09, 1.91] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.81 [0.51, 1.28] | | > 1 | | 0% | 2 studies (2/-) | 18.3 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 0.49 [0.18, 1.37] | | < 1 | | 92% | 3 studies (3/-) | 91.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.50 [0.18, 1.41] | | < 1 | | 87% | 3 studies (3/-) | 90.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.83 [0.65, 5.19] | | < 1 | | 0% | 3 studies (3/-) | 12.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.63 [0.33, 1.19] | | < 1 | | 0% | 3 studies (3/-) | 92.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.30 [0.03, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 83.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.21 [0.02, 2.39] | | < 1 | | 65% | 2 studies (2/-) | 89.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.36 [0.05, 2.42] | | < 1 | | 7% | 2 studies (2/-) | 85.3 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.87 [0.03, 25.93] | | < 1 | | 61% | 2 studies (2/-) | 53.1 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.82 [0.10, 6.89] | | < 1 | | 27% | 3 studies (3/-) | 57.1 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.91 [0.09, 9.13] | | < 1 | | 58% | 3 studies (3/-) | 53.3 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.79 [0.02, 40.48] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.56 [0.24, 1.30] | | < 1 | | 0% | 3 studies (3/-) | 91.0 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.00 [0.17, 23.06] | | < 1 | | 0% | 2 studies (2/-) | 29.0 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.29 [0.28, 5.84] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.72 [0.16, 3.25] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.48 [0.04, 5.32] | | < 1 | | 0% | 1 study (1/-) | 72.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.95 [0.09, 10.52] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.79 [0.02, 40.48] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.42 [0.08, 2.33] | | < 1 | | 0% | 3 studies (3/-) | 83.8 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.12] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.19 [0.01, 4.33] | | < 1 | | 0% | 1 study (1/-) | 84.8 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.17 [0.02, 1.78] | | < 1 | | 0% | 2 studies (2/-) | 92.8 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.79 [0.02, 40.48] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.79 [0.02, 40.48] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.38 [0.03, 4.32] | | < 1 | | 0% | 2 studies (2/-) | 78.2 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.07 [0.00, 1.17] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
